Organization | University of Tokyo

University of Tokyo Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4

Founded: Tokyo Japan (1886)

Organization Overview

First Clinical Trial

2002

NCT00200343

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2017

Timeline

NOW

Now

Alternative names

Department of Cardiovascular Medicine, University of Tokyo Graduate School of Medicine | Department of Gastroenterology, University of Tokyo | Department of Palliative Medicine, The University of Tokyo Hospital | Director, Research Hospital, Institute of Medical Science, Tokyo University | Division of Nephrology and Endocrinology University of Tokyo School of medicine | HONJO CLINIC II, Tokyo, Japan | Human Genome Center, Institute of Medical Science, University of Tokyo | Institute of Medical Science, The University of Tokyo | Professor, Department of Metabolic Diseases, Graduate School of Medicine, the University of Tokyo. | Professor, Department of Nephrology and Endocrinology, University of Tokyo Graduate School of Medicine | The Institutute of Medical Science, University of Tokyo | The University of Tokyo Hospital | Tokyo University

Active Ingredients

Drugs in Phase 4 Trials (8)

amlodipine (norvasc) (1 trial)

diclofenac (voltaren) (1 trial)

hydrochlorothiazide (esidrix) (1 trial)

insulin human (humulin) (1 trial)

pitavastatin (livalo) (2 trials)

telmisartan (micardis) (1 trial)

teneligliptin (Tenelia) (10 trials)

travoprost (travatan) (1 trial)

Drugs in Phase 3 Trials (6)

canagliflozin (invokana) (3 trials)

hepatitis b immune globulin (human) (BayHep B) (1 trial)

meglitinides (1 trial)

pioglitazone (actos) (1 trial)

sufonylurea (2 trials)

ursodeoxycholic acid (1 trial)

Drugs in Phase 2 Trials (36)

agatolimod (1 trial)

anastrozole (arimidex) (1 trial)

autologous dendritic cells (1 trial)

cdca1 (1 trial)

depdc1 (3 trials)

gemcitabine (gemzar) (5 trials)

gimeracil (1 trial)

hla-a*0201restricted urlc10 peptides with adjuvant (1 trial)

hla-a*02:01-restricted vegfr1-derived peptide vaccination (1 trial)

hla-a*2402 or a*0201 restricted peptides (1 trial)

hla-a*2402restricted urlc10, cdca1, and kif20a peptides with adjuvant (1 trial)

koc1 (4 trials)

montanide isa51 (2 trials)

mphosph1 (3 trials)

mt-3995 (2 trials)

NeoAntigen peptides (1 trial)

oteracil (1 trial)

oxaliplatin (eloxatin) (1 trial)

panobinostat (farydak) (1 trial)

perampanel (fycompa) (1 trial)

rnf43, tomm34, vegfr1, vegfr2 peptide vaccine (1 trial)

s-488410 (1 trial)

s-588410 (1 trial)

tamibarotene (1 trial)

tegafur (1 trial)

toremifene (fareston) (1 trial)

ttk-567 (5 trials)

urc10, ttk, koc1 (1 trial)

urlc10 (7 trials)

urlc10-177 (1 trial)

vegfr1 (9 trials)

vegfr1-1084 (2 trials)

vegfr1-a24-1084 (1 trial)

vegfr2 (9 trials)

vegfr2-169 (3 trials)

Drugs in Phase 1 Trials (19)

antiangiogenic peptide vaccine therapy (1 trial)

azd1656 (1 trial)

cdca1, urlc10, kif20a, depdc1 and mphosph1 (1 trial)

cisplatin (platinol) (1 trial)

egfrviii peptide (1 trial)

epha2 peptide (1 trial)

fluorouracil (efudex) (1 trial)

her2/neu peptide (1 trial)

hla-a*0201 or hla-a*0206-restricted urlc10 peptides (1 trial)

hla-a02 restricted hig2 (1 trial)

hla-a*2402-restricted cdca1 and kif20a peptides (1 trial)

hla-a*2402restricted urlc10, cdca1, and kif20a peptides (1 trial)

hla-a*2402restricted urlc10, cdca1, vegfr1 and vegfr2 (1 trial)

hla-a*2402restricted urlc10, ttk, vegfr1 and vegfr2 (1 trial)

il13r alpha peptide (1 trial)

ly6k, vegfr1, vegfr2 (1 trial)

ttk, ly6k, and imp-3 peptides (1 trial)

ykl-40 peptide (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Amyotrophic Lateral Sclerosis (Phase 2)

Bile Duct Neoplasms (Phase 1)

Breast Neoplasms (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Renal Cell (Phase 1)

Cholangiocarcinoma (Phase 1)

Colorectal Neoplasms (Phase 2)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Diabetic Nephropathies (Phase 2)

Esophageal Neoplasms (Phase 2)

Essential Hypertension (Phase 4)

Glucose Intolerance (Phase 4)

Hepatitis (Phase 3)

Hepatitis A (Phase 3)

Hepatitis C (Phase 3)

Hepatitis C, Chronic (Phase 3)

Hepatitis, Chronic (Phase 3)

Hyperemia (Phase 4)

Hypertension (Phase 4)

Kidney Diseases (Phase 2)

Leukemia (Phase 2)

Leukemia-Lymphoma, Adult T-Cell (Phase 2)

Leukemia, T-Cell (Phase 2)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 2)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Cutaneous (Phase 2)

Macular Degeneration (Phase 1)

Motor Neuron Disease (Phase 2)

Neoplasm Metastasis (Phase 1)

Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 2)

Rectal Neoplasms (Phase 2)

Recurrence (Phase 2)

Small Cell Lung Carcinoma (Phase 1)

Stomach Neoplasms (Phase 2)

Urinary Bladder Neoplasms (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 67
# of Trial APIs: 69